Navigation Links
MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
Date:10/29/2007

SAN FRANCISCO, October 29, 2007 MedImmune today announced results from a recent economic analysis of Synagis (palivizumab), a monoclonal antibody (MAb) that is the standard of care for prevention of severe lower respiratory tract infection due to respiratory syncytial virus (RSV) in high-risk infants. Released at the American Academy of Pediatrics (AAP) 2007 National Conference & Exhibition, the analysis evaluated the costs of providing Synagis to premature infants, as well as the potential health benefits and cost savings that could occur from lower rates of severe RSV infections.

RSV can cause severe lower respiratory tract infections in preterm infants. However, recent data have suggested that RSV infection early in an infants life may cause subsequent chronic respiratory complications such as persistent wheezing.

Dr. Mark Polak, a neonatologist and professor of pediatrics from the West Virginia University School of Medicine and lead author of the economic analysis, noted, We factored in the potential costs of possible future complications and the quality of life associated with persistent wheezing and, based on these assumptions, our study found that preventing RSV early in life makes economic sense.

The authors noted that more evidence is needed to substantiate the linkage between Synagis and subsequent reductions in persistent wheezing.


'/>"/>

Contact: Tor Constantino
301-398-5801
Edelman Public Relations
Source:Eurekalert

Page: 1

Related medicine news :

1. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
2. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
3. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
4. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
5. Monogram Presents Results of First ETag Breast Cancer Studies
6. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
7. Fresh warnings to doctors regarding abortion pill
8. Researchers Present Data Regarding The Efficiency Of Herbs
9. Will anxiety regarding fertility treatment affect the chances of conception?
10. Changing Trends Regarding Insurance Cover For Weight Reduction Surgery
11. Indian Government warns Gujarat regarding possibility of bird flu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... FOR INFORMATION: ... AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is the ... perioperative nurses in attendance to study the latest evidence-based recommendations and resources ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown ... to reduce the frequency and level of relapse. , At the ... and Purpose,” will explore the critical tasks of the recovery phase and beyond ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Today, the Whole-Food ... announced that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, ... Network. , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... announce the addition of micro-needling services in their Napa Valley office. The technique ... of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 Aethlon ... Jim Joyce , Chairman and CEO, will be presenting at ... New York, NY at 2:15 p.m. ... participate in an Immunotherapy Panel discussion taking place at 3:15 ... available for replay approximately one hour after the conclusion of ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... announced underwritten secondary offering of 11,027,558 shares of its ... affiliates of Blackstone and Goldman Sachs.  The shares are ... of $96.45 per share. The selling stockholders will receive ... Biomet nor any of its directors, officers or other ...
Breaking Medicine Technology: